Alert, but not alarmed - a comment on "Towards more accurate HIV testing in sub-Saharan Africa: a multi-site evaluation of HIV RDTs and risk factors for false positives (Kosack et al. 2017)". by Johnson, Cheryl C et al.
Letter to the editor
Alert, but not alarmed - a comment on “Towards more
accurate HIV testing in sub-Saharan Africa: a multi-site
evaluation of HIV RDTs and risk factors for false
positives (Kosack et al. 2017)”
Cheryl C. Johnson1§, Anita Sands2, Willy Urassa2 and Rachel Baggaley1
§Corresponding author: Cheryl C Johnson, Department of HIV, World Health Organization, 20 Avenue Appia, Geneva 1201, Switzerland. Tel: +41 22 791 4335.
(Johnsonc@who.int)
Keywords: HIV; diagnostic; test; quality; misdiagnosis; false positive; Africa
Received 28 April 2017; Accepted 2 June 2017; Published 19 June 2017
Copyright: © 2017 Johnson CC et al; licensee International AIDS Society. This is an Open Access article distributed under the terms of the Creative Commons
Attribution 3.0 Unported (CC BY 3.0) License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Dear Editors,
We read with interest Kosack and colleagues’ article [1],
which evaluated eight HIV rapid diagnostic tests (RDTs)
using specimens collected from Médecins Sans Frontières
(MSF) sites, between 2011 and 2015, in five African coun-
tries. Authors state that RDT accuracy differed from previous
evaluations conducted by the World Health Organization
(WHO), concluding only one HIV RDT achieved WHO prequa-
lification performance criteria and none met WHO perfor-
mance thresholds when using the “lower end of the 95% CI”.
Authors attributed such “poor performance”, primarily poor
specificity, to the RDTs and possible non-specific geographi-
cal and population-level interferrents.
Overall, we agree with the author’s findings and their con-
clusions, which affirm WHO recommendations to use a vali-
dated testing algorithm. However, we do not agree with the
author’s discussion, which is at odds with WHO’s data and
suggests misdiagnosis of HIV occurred and can be attributed
to WHO-prequalified RDTs. Given the limitations of the evi-
dence presented, we find their discussion to be potentially
misleading.
The authors report that they found a substantial number
of false reactive test results resulting in poor positive pre-
dictive values. This finding is based on the result of a single
HIV RDT. A single reactive test result is never sufficient to
make an HIV-positive diagnosis. To provide a definitive HIV
diagnosis, WHO recommends countries use a high (≥5%) or
low (<5%) prevalence testing strategy comprised of up to
three RDTs as part of a validated testing algorithm [2].
Thus, it is incorrect for the authors to discuss these findings
in the context of “misdiagnosis”, as no evidence of actual
misdiagnosis (false positive or false negative diagnoses) is
presented. In fact, while not noted by the authors, if all
study sites used the data from Table 2 and adhered to
WHO recommendations, all settings could construct a
highly accurate testing algorithm and thereby provide
highly accurate HIV diagnoses.
While the authors acknowledge that some studies have
found HIV RDT performance, particularly specificity, to vary
across populations and settings due to cross-reacting anti-
bodies [3–9], they state that their study relied on self-
reported morbidities and did not find a significant associa-
tion with false reactive results. However, Table 7 suggests
that self-reported “malaria” was associated with false reac-
tive test results on one RDT (2.62, 95% confidence interval
[CI]: 1.21–5.6). In the absence of a review of clinical records
and patient information, it is not known what other morbid-
ities or factors may have contributed to these results.
Authors also did not provide details on the sites where the
specimens were collected, or the testing algorithms used at
each site. Without knowing the testing algorithms, it is not
known if the specimens were characterized correctly.
Between 2011 and 2015 it is known that some of the study
countries utilized a “tiebreaker” approach to resolve discre-
pant test results and rule in HIV infection, instead of con-
sidering these results as “inconclusive” and retesting
patients in 14 days as recommended by WHO [2]. Previous
studies have demonstrated this to be a possible cause of
false positive results and misdiagnoses [10–18]. Thus, if
these suboptimal testing strategies were used at site level,
the study may have included “inconclusive” specimens that
were misclassified as “HIV-positive” specimens. This could
explain the high proportion of false reactive results
observed.
Lastly, although the authors report this as a systematic head-
to-head evaluation, it should be clarified that this study did not
conduct a systematic head-to-head comparison of MSF and
WHO evaluations. Authors do not discuss methodological dif-
ferences between WHO performance evaluations and those
presented by the authors; namely that WHO evaluations are
conducted using specimens collected worldwide. WHO
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performance criteria are based on RDTs achieving ≥99% sensi-
tivity and ≥98% specificity as a fixed proportion because char-
acterized HIV-positive and HIV-negative specimens are used
[19]. Using a 95% CI is only relevant if one is making an
inference to the population where the specimens originated
and the true HIV status of the specimens is unknown.
Therefore, using the lower end of the 95% CI as a point of
comparison between WHO and MSF evaluations is irrelevant
and misleading.
This study presents important results and affirms the impor-
tance of using a validated testing algorithm, as recommended
by WHO. While we concur with their conclusion, the author’s
discussion points are not supported by the evidence in this
article. Authors should reconsider their remarks or provide
evidence indicating actual misdiagnosis, attributable to RDT
performance alone.
This evidence should be viewed in the broader context of HIV
diagnosis. Countries must be advised that WHO-prequalified
HIV RDTs are accurate and can be used to provide a reliable HIV
diagnosis. Nevertheless, countries and programmes need to
ensure that they are following WHO-recommended HIV testing
strategies and use a validated testing algorithm.
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